Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
|Articles|June 18, 2015
Lonza to Build Gene and Cell Therapies Facility in Houston
Author(s)BioPharm International Editors
Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies
Advertisement
Lonza announced on June 16 the planned construction of a 100,000-sq-ft facility for viral and immunotherapy development and manufacturing in the Houston, TX area. The new facility will more than double Lonza’s capacity for the production of viral gene and virally modified therapeutics and will include a segregated fill/finish suite, the company reports.
The multi-purpose facility is expected to come on-line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
3
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
4
UCB Reports 24-Week Bimekizumab (Bimzelx) vs Risankizumab Data in PsA
5